The independent peptide encyclopedia
The clear, cited reference for
peptide research & news.
Structured profiles, catalogued studies, and a daily news desk, sourced, tiered by evidence, and reviewed before publishing. No clinic affiliation, no funnels, no hype.
Try BPC-157, BPC-157 vs TB-500, tendon repair, or browse A-Z →
- 102
- Peptide profiles
- 1,280+
- Catalogued studies
- 4
- Evidence tiers
- 100%
- Independent
Browse the spine
Explore by category
Ten body-system and goal-based hubs organize every profile, study, and guide.
The reference layer
Featured profiles
Each profile carries an at-a-glance data card, mechanism, evidence summary, and linked studies.
BPC-157
Body Protection Compound 157
BPC-157 is a lab-made peptide based on a protein found in stomach fluid. In animal studies it appears to speed the healing of tendons, muscle, and the gut lining. Human evidence is still very limited, so what we know comes mostly from rodents, not people.
Read profileDihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is an experimental compound derived from angiotensin IV, studied in animals for its effects on memory and synapse formation. There are no published human trials, so its effects and safety in people are unknown.
Read profileSS-31
SS-31 (Elamipretide)
SS-31, known in clinical development as elamipretide, is a mitochondria-targeting peptide studied for diseases involving mitochondrial dysfunction, including some heart and rare mitochondrial conditions. It has reached human trials, but results have been mixed and it is not approved. Longevity claims go beyond the current evidence.
Read profileThe news desk
Latest in peptide research
- Regulatory
FDA updates compounding guidance affecting GLP-1 availability
New agency guidance narrows when compounding pharmacies may prepare certain GLP-1 and related peptide products, with knock-on effects for supply.
- Research
Meta-analysis pools GHRH-analog trials on lean body mass
A new pooled analysis combines randomized trials of growth-hormone-releasing-hormone analogs and reports modest effects on lean mass, with notable limitations.
- Longevity
New cellular-senescence assay renews interest in bioregulators
A preprint describes a faster screening assay for cellular senescence that researchers are using to revisit peptide bioregulators such as epitalon.
Why you can trust this
Editorial standards, in the open
Every reference page is written and reviewed by qualified clinicians and scientists, carries a last-reviewed date, and shows the evidence tier behind each claim. Our methodology, sourcing, and corrections policy are public. For now we publish under the Peptide.it editorial team rather than individual bylines.
- 4evidence tiers, flagged on every claim
- 100%human-reviewed before publishing
- 0clinic or pharmacy affiliations